$SGRY

Surgery Partners, Inc. (SGRY): Entry into a Material Definitive Agreement

Surgery Partners, Inc. (SGRY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. sgry-20260721 0001638833 FALSE 07/21/2026 0001638833 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

Original reporting
Published Jul 24, 2026, 1:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$SGRY
Bullish
medium confidence
Mentioned
$SGRY
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SGRYBullishMed
01

Why it matters

If approvals and regulatory conditions are met, SGRY would receive total consideration of about $795M, but final net cash proceeds remain uncertain due to customary purchase price adjustments and closing conditions.

02

Market read

Traders can reassess deal-close probability, expected cash proceeds range (directionally), and risk around regulatory and physician-approval milestones.

03

What to watch

Final cash proceeds are subject to purchase price adjustments (indebtedness, working capital, transaction expenses), and the outside date is defined relative to escrow signature release, not the filing date.

Relevance 6/10Novelty 8/10Timing: Filed today on SEC 8-K, with transaction terms and escrow release conditions disclosed.

Background

SGRY filed an 8-K describing escrowed signature pages for two securities purchase agreements to sell ownership interests in Mountain View Hospital, LLC and Idaho Falls Community Hospital, LLC to Intermountain Health.

Company-level read

Ticker impact

$SGRYBullishMedium confidence
Context

Surgery Partners disclosed an agreement for Intermountain Health to buy its Idaho Falls facilities, with ~$795M total consideration and escrowed closing conditions.

Expected impact

Likely supportive for SGRY on deal value, but tempered by escrow release conditions, regulatory approvals, and the 60-day outside date after escrow release.

Evidence & confidence

The filing provides deal structure, valuation ($1.15B facilities), consideration (~$795M), and key gating items (physician approvals, certifications, HSR, regulatory approvals, third-party consents). However, it does not provide final net cash proceeds or timing certainty beyond the outside date framework.

Market effects

Signals continued consolidation in hospital ownership, potentially affecting deal expectations and valuation benchmarks for other healthcare operators.

Could shift healthcare facility ownership and local payer/provider dynamics in Idaho Falls and Mountain View markets.

Limited direct global impact; primarily a US healthcare M&A and asset-rotation story.

Counterpoint

The transaction may not close smoothly due to physician governing board approvals, HSR timing, and third-party consents, so near-term price may overreact to headline consideration.

Key entities

  • Surgery Partners, Inc.

    Seller in the escrowed agreements to sell hospital ownership interests to Intermountain Health.

  • Intermountain Health

    Buyer under the securities purchase agreements for MVH and IFCH facilities.

  • Mountain View Hospital, LLC (MVH)

    Hospital ownership interest included in the transaction; physician approvals required for escrow release.

  • Idaho Falls Community Hospital, LLC (IFCH)

    Hospital ownership interest included in the transaction; sale announced via press release exhibit.

Related articles

$SGRYMed

Why Is Surgery Partners Stock Gaining Friday? - Surgery Partners (NASDAQ:SGRY)

Surgery Partners (SGRY) said it will sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $795 million, valuing the facilities at roughly $1.15 billion, subject to physician partner approval. The company reaffirmed fiscal 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million.

$SGRYMedAI 8/10

Surgery Partners jumps on $1.15B hospital sale deal By Investing.com

Surgery Partners (NASDAQ:SGRY) rose 5.8% after agreeing to sell two Idaho Falls hospitals to Intermountain Health for about $1.15B. Surgery Partners expects about $795M for its ownership interests, with cash proceeds subject to purchase price adjustments. The deal needs approvals and regulatory steps and is expected to close in coming months. 2026 outlook was reaffirmed excluding the deal.

$SGRYMedAI 8/10

Surgery Partners To Sell 2 Idaho Hospitals To Intermountain For $795 Mln, Backs FY View; Shares Jump

Surgery Partners (SGRY) said it signed agreements to sell its interests in Mountain View Hospital and Idaho Falls Community Hospital in Idaho to Intermountain Health for about $795 million. The hospitals were valued around $1.15 billion. Surgery Partners reaffirmed its FY2026 revenue of $3.35B to $3.45B and adjusted EBITDA of at least $530M excluding the deal. Shares rose to about $16.51.

$SGRYMed

Why Surgery Partners (SGRY) Stock Is Trading Up Today

Surgery Partners (SGRY) shares rose about 2.7% in the morning to around $17.15 after Cantor Fitzgerald reiterated an “Overweight” rating and set an $18.00 price target. Cantor cited some softness in Q2 ambulatory surgery center and outpatient nursing data, but kept a positive view. Other analysts expect profitability this year.

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.